Woodford's Full Portfolio Revealed

Woodford is maximising his overseas exposure and allocating a third of the portfolio to his favourite sector, pharmaceuticals, as well as a surprisingly high financials exposure

Emma Wall 14 July, 2014 | 1:11PM

Neil Woodford has revealed his entire portfolio of holdings for the recently launched Woodford Equity Income fund.

Before the launch of the fund last month, Woodford said that “Woodford Funds as a company will be a very different offering – but expect business as usual when it comes to stock selection and the running of the new income fund.”

Woodford has long been a champion of both pharmaceutical and tobacco stocks, and the new fund’s portfolio does not disappoint. The top 10 stocks released last week revealed AstraZeneca (AZN) and GlaxoSmithKline (GSK) were the top two holdings, with Roche (RO) coming in sixth position. But some investors may be surprised at just how high a conviction Woodford has in the sector – a further 14 health care stocks are in the fund’s portfolio.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC7,521.00 GBP0.00
e-Therapeutics PLC5.05 GBP0.00
G4S PLC201.30 GBP0.00
GlaxoSmithKline PLC1,667.00 GBP0.00
HSBC Holdings PLC551.90 GBP0.00
LF Woodford Equity Income A Sterling Acc20.22 GBP-1.02
Next PLC7,066.00 GBP0.00
ReNeuron Group PLC140.50 GBP0.00
Roche Holding AG339.80 CHF0.00
Sanofi SA93.71 EUR0.00
Serco Group PLC156.30 GBP0.00
Smith & Nephew PLC1,827.00 GBP0.00
Velocys PLC4.76 GBP0.00

About Author

Emma Wall  is former Senior International Editor for Morningstar

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites